In the News

Connect with us

Stay Informed.
Get the latest news and updates on MSK’s cancer care and research breakthroughs sent straight to your inbox with our e-newsletters.
Newsletter Sign Up
386 News Items found
Fiona and Stanley Druckenmiller
Donors on a Mission to Fast-Track Cancer Therapies at MSK

Meet Fiona and Stanley Druckenmiller, whose latest venture supports promising new avenues of research for experts at Memorial Sloan Kettering Cancer Center.
An immunofluorescence image of an aged mouse liver
Top Cancer Research Advances at MSK in 2024

MSK researchers continued to make strides against cancer in 2024. Learn about some of their top discoveries.
MSK President Craig Thompson
New Collaboration Will Accelerate US-China Clinical Trials

In a first-of-its-kind collaboration, MSK has joined forces with the Chinese Thoracic Oncology Group in an effort to establish a program of clinical trials that are open to patients from both the United States and China.
Charles Rudin with lab member
ASCO 2020: Advances in the Treatment of Small-Cell Lung Cancer

During the upcoming ASCO Virtual Scientific Program, MSK Chief of Thoracic Oncology Service Charles M. Rudin, MD, PhD, will present a study that found pembrolizumab addition to first-line chemotherapy significantly improved progression-free survival for patients with small cell lung cancer (SCLC).
MSK's Justin Jee, MD, PhD, and Ed Reznik, PhD, are seen smiling.
New Insights Into How Obesity Influences Cancer Driver Mutations

Learn about research at MSK that finds obesity can influence driver mutations that produce specific subtypes of cancers, including lung and endometrial cancers.
Microscope image showing lung metastasis
TGF-Beta and RAS Signaling Are Both Required for Lung Cancer Metastasis, Study Finds

MSK researchers have identified two signaling pathways that work together to spur the spread of lung cancer. Taking away one of those signals could help slow or stop metastasis, findings in animal models suggest.
Dr. Piro Lito
In the Lab
Potential Drug Shows Promise Targeting a Range of KRAS-Driven Cancers in the Lab

MSK investigators report exciting results for a new molecule that can block 16 different mutated forms of the KRAS protein. In the lab, the compound was effective against many cancer cell lines and in mouse models of lung cancer and colorectal cancer.
Dr. Karuna Ganesh and Elizabeth Benitez in the lab.
How a Better Understanding of Metastasis May Lead to Better Cancer Treatment

Metastasis is responsible for about 9 of every 10 cancer deaths, and it remains one of the most daunting and least understood aspects of the disease. Researchers across MSK are approaching a wide variety of metastatic cancer types from many directions.
MSK medical oncologist Michael Morris
Researching New Treatments for Neuroendocrine Prostate Cancer (NEPC)

Learn about MSK's specialty in treating neuroendocrine cancers.
Promising Data for RET Fusion-Positive Lung Cancer Patients with Targeted Therapy, Selpercatinib, Presented at the 2019 World Congress on Lung Cancer

Selpercatinib (also known as LOXO-292) is a highly selective RET inhibitor with activity against diverse RET fusions, activating RET mutations and brain metastasis. Phase 1/2 data from the LIBRETTO-001 trial presented at the IASLC 2019 World Conference on Lung Cancer demonstrates selpercatinib’s marked antitumor activity in RET fusion-position non-small cell lung cancer (NSCLC) patients. These findings, presented by Alexander Drilon, MD, principal investigator and Research Director of Early Drug Development at Memorial Sloan Kettering Cancer Center, will form the basis of an US Food and Drug Administration new drug application submission.